Colchicine and/or Naltrexone for Hospitalized COVID-19 Patients Not Requiring High Levels of Ventilatory Support (COLTREXONE): A Prospective, Randomized, Open-Label Trial.

Cureus · 2024 · PMC11178333 · PMID 38883032

Europe PMC DOI

hedged sentence

0.5400

closest p · 10.8× alpha

0.5400

boldest claim

The sentences

showed a trendp=0.54not close (p > 0.1)

Regression estimates showed a trend toward a prolonged time to recovery with LDN (aHR 0.89; 95% CI: 0.63-1.28, p=0.54) and a trend toward a decrease in the day of disease recovery and LOE with colchicine (aHR 1.32; 95% CI: 0.91-1.82, p=0.16).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.